Exchange: NASDAQ·Updated 07:51 PM EDT
News
all
press releases
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +22.22% and +6.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.
Zacks
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.
Zacks
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Zacks
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 25.79%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of...
MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 3,172 Shares
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Watanabe sold 3,172 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $74,890.92. Following the sale, the insider owned 720,755...
MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Sells $31,661.01 in Stock
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) CFO Latha Vairavan sold 1,341 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $31,661.01. Following the completion of the transaction, the chief financial...
MarketBeat

Advertisement|Remove ads.